Scaled Microbiomics (SMB) has a new biotech opportunity designed for those who want to make a difference in the next stages of our healthcare evolution – improving human health by rebalancing microbiomes.
Scaled Microbiomics (SMB) has a new biotech opportunity designed for those who want to make a difference in the next stages of our healthcare evolution – improving human health by rebalancing microbiomes.
SMB is designing a drug development platform to identify, test, and market a new class of products to help people suffering from – or at risk for – a broad range of diseases. Our first disease targets are gut disorders associated with microbiome imbalance. These include:
- Inflammatory Bowel Diseases (IBD) such as Crohn’s Disease and Ulcerative Colitis
- Colorectal Cancers (CRC)
- Enteric Infectious Diseases, especially Travelers’ Diarrhea
- Small Intestinal Bacterial Overgrowth (SIBO), a cause of after-meal abdominal distress
All of these disorders are closely linked to biological imbalances in gut microbiomes, a newly-discovered area for treating diseases not only in the gut, but also throughout the body.
Why Should Microbiome-Related Health Be Important to You?
“Microbiome is one of the fastest growing fields in biology. It is poised to grow by USD 276.93 million during 2020-2024, at a combined annual growth rate (CAGR) of almost 15% in that period.”
-MarketWatch
“Microbiome therapeutics has emerged as the red-hot scientific area… and source of new business opportunities and collaborations. Growing awareness about microbiome therapeutics has also encouraged many leading pharmaceutical companies to enter into the global microbiome therapeutics market through mergers and acquisitions.”
-Fortune Business Insights
Why Should Microbiome-Related Health Be Important to You?
“Microbiome is one of the fastest growing fields in biology. It is poised to grow by USD 276.93 million during 2020-2024, at a combined annual growth rate (CAGR) of almost 15% in that period.”
-MarketWatch
“Microbiome therapeutics has emerged as the red-hot scientific area… and source of new business opportunities and collaborations. Growing awareness about microbiome therapeutics has also encouraged many leading pharmaceutical companies to enter into the global microbiome therapeutics market through mergers and acquisitions.”
-Fortune Business Insights
SMB's Lead Treatment Target Markets Are Growing
IBD
Market USD 15.9 billion in 2018; CAGR of 4.4% for 2018 to 2026
CRC
Market $13.7 billion in 2018; CAGR of 6.1% for 2018 to 2023
Travelers’ Diarrhea
Market $738 million in 2018; CAGR of 7% for 2019-2027
Even more excitingly, microbiomes are increasingly being understood as critical determinants of health even outside of the gut – strong evidence suggests roles for microbiomes especially in those frustrating diseases for which modern medicine has no cure, like obesity, heart disease, diabetes, liver disease, major depression, Alzheimer’s and Parkinson’s diseases, and even osteoporosis, to name just a few.
What Are Microbiomes Anyway?
Microbiomes – the crucial, invisible ecosystems of microorganisms that live in and on every human surface – are increasingly being found to have vast impacts on human health. Those impacts are most obvious in the gut, where microbiome composition (who’s there?) and function (what are they doing?) influence a person’s risk for getting cancer, digestive diseases, and inflammatory syndromes like inflammatory bowel disease.
What Are Microbiomes Anyway?
Microbiomes – the crucial, invisible ecosystems of microorganisms that live in and on every human surface – are increasingly being found to have vast impacts on human health. Those impacts are most obvious in the gut, where microbiome composition (who’s there?) and function (what are they doing?) influence a person’s risk for getting cancer, digestive diseases, and inflammatory syndromes like inflammatory bowel disease.
Even more excitingly, microbiomes are increasingly being understood as critical determinants of health even outside of the gut – strong evidence suggests roles for microbiomes especially in those frustrating diseases for which modern medicine has no cure, like obesity, heart disease, diabetes, liver disease, major depression, Alzheimer’s and Parkinson’s diseases, and even osteoporosis, to name just a few.
How is SMB Different?
Most companies developing microbiome therapeutics focus on adding beneficial microbes to an imbalanced gut (specialized versions of probiotics). While promising, this approach is as yet unproven and faces many scientific, technical, and regulatory hurdles.
SMB takes a unique approach – we seek to reduce the number and influence of microbes known to negatively affect gut health and microbiome balance. SMB’s patent-pending technology uses natural biological agents to prevent these microbes from exerting their deleterious effects on our health. SMB’s approach faces far fewer hurdles en route to FDA approval – and the “platform” approach we take means that we can continuously develop new treatments as microbiome science steadily advances. SMB has filed a total of six international patents to date, with many more in the pipeline.*
*More details are available upon execution of a non-disclosure agreement (NDA).
SMB Actively Seeking Interested Partners To Help Us Grow
And Accelerate Our R&D Pathway
SMB is seeking to raise capital from accredited investors, foundations, government entities, family offices, corporations and the like to advance drug candidates faster to FDA approval. SMB’s Travelers’ Diarrhea formulation will be marketed as a dietary supplement initially. With proper investment levels SMB intends to pursue the FDA drug approval process, aiming to have FDA-approved products within 3-5 years. and with proper investment can be on the market in 2021, with FDA-approved drugs appearing within 3-5 years.*
*More details are available upon execution of a non-disclosure agreement (NDA).
Interested in Learning More?
To learn more about SMB, its leadership and scientific team, its patent portfolio, and its plans, please contact us using the form below. Serious investors may then execute a non-disclosure agreement (NDA) to continue discussions, learn the company’s current valuation, and more.
Interested in Learning More?
To learn more about SMB, its leadership and scientific team, its patent portfolio, and its plans, please contact us using the form below. Serious investors may then execute a non-disclosure agreement (NDA) to continue discussions, learn the company’s current valuation, and more.
